Mirum Pharmaceuticals (MIRM) Net Margin (2021 - 2026)

Mirum Pharmaceuticals' Net Margin history runs 6 years deep, the most recent figure standing at 494.21% for Q1 2026.

• In Q1 2026, Net Margin fell 48106.0% year-over-year to 494.21%; the TTM figure through Mar 2026 stood at 140.24% (down 11985.0% YoY), while the FY2025 annual figure was 4.48%, up 2162.0% from the prior year.
• Net Margin was 494.21% for Q1 2026 at Mirum Pharmaceuticals, down from 3.85% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 2.18% in Q3 2025 to a low of 494.21% in Q1 2026.
• Historically, Net Margin has averaged 104.39% across 5 years, with a median of 49.42% in 2023.
• Biggest YoY gain for Net Margin was 75203 bps in 2022; the steepest drop was 196439 bps in 2022.
• A 5-year view of Net Margin shows it stood at 130.55% in 2022, then surged by 61 bps to 51.27% in 2023, then soared by 53 bps to 23.93% in 2024, then jumped by 84 bps to 3.85% in 2025, then slumped by 12745 bps to 494.21% in 2026.
• The last three Net Margin figures came in at 494.21% (Q1 2026), 3.85% (Q4 2025), and 2.18% (Q3 2025), per Business Quant data.